Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News BioMerieux to develop companion test for breast cancer drug

BioMerieux to develop companion test for breast cancer drug

18th September 2007

BioMerieux has announced an agreement with Ipsen whereby it will develop a companion test for a breast cancer drug that is currently being evaluated by Ipsen.

An examination will be developed by bioMerieux to complement Ipsen’s BN 83495 drug – the assay will ascertain which patients are most suitable to undergo new inhibitor treatments.

Presently in phase I of clinical development, Ipsen’s BN 83495 therapy is designed to block the steroid sulfatase enzyme found in hormone-dependent breast cancer in post menopausal women, according to the company.

The test will use bioMerieux’s Nasba amplification technology and will be developed on the firm’s NucliSENS EasyQ molecular diagnostics platform.

Chief executive of bioMerieux Stephane Bancel commented: "By teaming our expertise with that of biopharmaceutical companies, bioMerieux’s goal is to contribute towards making the best medicine available to the right patients, while optimising health costs."

It was recently reported that bioMerieux acquired Australian firm BTF.
ADNFCR-1050-ID-18283863-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.